Business Context and Reporting Period
This Form 8-K Current Report was filed by Salarius Pharmaceuticals, Inc. (not Decoy Therapeutics Inc.) on March 10, 2023. The filing addresses a specific event under Item 8.01 (Other Events) regarding the company's banking relationships during the period of financial instability affecting Silicon Valley Bank.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report is limited to a qualitative disclosure regarding the location of the company's cash deposits.
Material Changes
There are no material changes to financial performance or operations reported in this document. The sole material disclosure is a confirmation that the company does not hold cash deposits or securities at Silicon Valley Bank.
Guidance, Outlook, and Risks
Management Commentary: The company explicitly informed investors of its lack of exposure to Silicon Valley Bank to mitigate concerns regarding liquidity and asset safety.
Risks and Contingencies: The filing addresses the risk of asset seizure or loss associated with the Silicon Valley Bank situation by confirming no exposure exists.
Investor Verification Checklist
- Verify the registrant name is Salarius Pharmaceuticals, Inc. (SLRX), not Decoy Therapeutics Inc.
- Confirm the company has no cash deposits or securities held at Silicon Valley Bank as of March 10, 2023.
- Note that this filing contains no financial performance data or forward-looking guidance.